| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $8.2M | — | -37.6% |
| SG&A Expense | $5.1M | — | +4.5% |
| Operating Income | -$13.3M | — | +26.2% |
| Interest Expense | $1.4M | — | +8.3% |
| Net Income | -$13.5M | — | +25.2% |
| EPS (Basic) | -$0.28 | — | +30.0% |
| EPS (Diluted) | -$0.28 | — | +30.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $46.5M | -18.6% | -49.5% |
| Current Assets | $48.7M | -16.8% | -48.4% |
| Total Assets | $58.0M | -16.4% | -45.9% |
| Current Liabilities | $38.5M | +6.6% | +230.1% |
| Long-term Debt | $32.1M | +0.0% | +0.0% |
| Total Liabilities | $45.8M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$10.6M | — | +44.1% |
| -8.2% |
| Stockholders' Equity | $12.2M | -50.8% | -78.7% |